Ultragenyx Pharmaceutical Inc. (RARE)
NASDAQ: RARE · Real-Time Price · USD
29.78
+0.26 (0.88%)
At close: Aug 22, 2025, 4:00 PM
30.13
+0.35 (1.18%)
After-hours: Aug 22, 2025, 7:08 PM EDT

Ultragenyx Pharmaceutical Stock Forecast

Stock Price Forecast

The 14 analysts that cover Ultragenyx Pharmaceutical stock have a consensus rating of "Strong Buy" and an average price target of $86.64, which forecasts a 190.93% increase in the stock price over the next year. The lowest target is $34 and the highest is $140.

Price Target: $86.64 (+190.93%)
Analyst Consensus: Strong Buy
TargetLowAverageMedianHigh
Price$34$86.64$80$140
Change+14.17%+190.93%+168.64%+370.11%

Analyst Ratings

The average analyst rating for Ultragenyx Pharmaceutical stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.

Recommendation Trends

RatingMar '25Apr '25May '25Jun '25Jul '25Aug '25
Strong Buy666565
Buy8810998
Hold111111
Sell000000
Strong Sell000000
Total151517151614

Latest Forecasts

AnalystFirmRatingRatingActionPrice TargetUpsideDate
Canaccord Genuity
Canaccord Genuity
Strong Buy
Maintains
$136$128
Strong BuyMaintains$136$128+329.82%Aug 8, 2025
Cantor Fitzgerald
Cantor Fitzgerald
Buy
Maintains
$112$105
BuyMaintains$112$105+252.59%Aug 6, 2025
HC Wainwright & Co.
HC Wainwright & Co.
Strong Buy
Initiates
$80
Strong BuyInitiates$80+168.64%Jul 28, 2025
Wedbush
Wedbush
Hold
Maintains
$35$34
HoldMaintains$35$34+14.17%Jul 14, 2025
Morgan Stanley
Morgan Stanley
Buy
Maintains
$65$55
BuyMaintains$65$55+84.69%Jul 14, 2025
More Analyst Ratings

Financial Forecast

Revenue This Year
670.68M
from 560.23M
Increased by 19.72%
Revenue Next Year
826.88M
from 670.68M
Increased by 23.29%
EPS This Year
-5.14
from -6.29
EPS Next Year
-4.12
from -5.14
Fiscal YearFY 2020FY 2021FY 2022FY 2023FY 2024FY 2025FY 2026FY 2027
Period EndingDec 31, 2020Dec 31, 2021Dec 31, 2022Dec 31, 2023Dec 31, 2024Dec 31, 2025Dec 31, 2026Dec 31, 2027
Revenue
271.03M351.41M363.33M434.25M560.23M670.68M826.88M1.22B
Revenue Growth
161.32%29.66%3.39%19.52%29.01%19.72%23.29%47.91%
EPS
-3.07-6.70-10.12-8.25-6.29-5.14-4.12-1.01
EPS Growth
--------
Forward PE
--------
No. Analysts
-----232218
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.

Revenue Forecast

Revenue20252026202720282029
High702.0M1.1B1.7B
Avg670.7M826.9M1.2B
Low628.9M659.7M762.8M

Revenue Growth

Revenue Growth20252026202720282029
High
25.3%
61.0%
109.7%
Avg
19.7%
23.3%
47.9%
Low
12.3%
-1.6%
-7.7%

EPS Forecast

EPS20252026202720282029
High-2.41-1.111.52
Avg-5.14-4.12-1.01
Low-6.56-5.93-4.19

EPS Growth

EPS Growth20252026202720282029
High---
Avg---
Low---
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.